<SEC-DOCUMENT>0001104659-24-038166.txt : 20240325
<SEC-HEADER>0001104659-24-038166.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325074033
ACCESSION NUMBER:		0001104659-24-038166
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20240325
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		24776903

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm249466d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:syn="http://syntheticbiologics.com/20240325">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_syn_syntheticbiologics.com_20240325 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20240325_20240325 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:AmendmentFlag" id="ixv-282">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityCentralIndexKey" id="ixv-283">0000894158</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20240325.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-03-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-25</xbrli:startDate>
        <xbrli:endDate>2024-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20240325__20240325_ztxBK5toiAVb"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:DocumentType" id="ixv-303">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_905_edei--DocumentPeriodEndDate_c20240325__20240325_zWHY6mc2IHXi"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-304">March 25, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityRegistrantName_c20240325__20240325_zsTjYxrf153e"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityRegistrantName" id="ixv-305">THERIVA BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240325__20240325_zNGtL6JhJjr"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-306">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityFileNumber_c20240325__20240325_zHYCKLAPh76k"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityFileNumber" id="ixv-307">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20240325__20240325_zrpfZgDAkjug"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityTaxIdentificationNumber" id="ixv-308">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation)</p></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20240325__20240325_z8NwkE0oGBif"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityAddressAddressLine1" id="ixv-309">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20240325__20240325_zmowoGq7qzS8"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityAddressAddressLine2" id="ixv-310">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20240325__20240325_zSbJcv2l3Ylg"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityAddressCityOrTown" id="ixv-311">Rockville</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20240325__20240325_z3UgSwj13l3h"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-312">Maryland</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20240325__20240325_zg5Qy9l6Q5P4"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:EntityAddressPostalZipCode" id="ixv-313">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_908_edei--CityAreaCode_c20240325__20240325_z5NZBQQvsGG2"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:CityAreaCode" id="ixv-314">301</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20240325__20240325_zhPwODkHXeGe"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:LocalPhoneNumber" id="ixv-315">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20240325__20240325_zeIHAqPPAlp6"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="ixv-316">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90C_edei--SolicitingMaterial_c20240325__20240325_zTE9xyhRL0C2"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="ixv-317">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_901_edei--PreCommencementTenderOffer_c20240325__20240325_ziLx2SWcNSl8"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer" id="ixv-318">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font: 10pt Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20240325__20240325_z5nBp8C5Umzb"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="ixv-319">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20240325__20240325_zAM4aXleLBrf"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:Security12bTitle" id="ixv-320">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20240325__20240325_zIf9xS5gkNT8"><ix:nonNumeric contextRef="AsOf2024-03-25" name="dei:TradingSymbol" id="ixv-321">TOVX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--SecurityExchangeName_c20240325__20240325_zaSID4vuGgQa"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-322">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20240325__20240325_z5V8e2STKIr8"><ix:nonNumeric contextRef="AsOf2024-03-25" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-323">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 11%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.02.</b></span></td>
    <td style="width: 89%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations and Financial Condition.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 25, 2024, Theriva Biologics, Inc., a Nevada corporation (the
&#8220;Registrant&#8221;) issued a press release that included financial information for its fiscal year ended December 31, 2023. A copy
of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 2.02 and in the press
release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1
to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission
made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 11%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="width: 89%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;</span></td>
    <td style="width: 96%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 89%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="tm249466d1_ex99-1.htm">99.1</a></span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="tm249466d1_ex99-1.htm">Press Release issued by Theriva Biologics, Inc., dated March 25, 2024</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.2pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 25, 2024</span></td>
    <td colspan="3" style="padding-right: 2.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERIVA BIOLOGICS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 3%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 3%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 44%; padding-right: 0.8pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm249466d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva&trade; Biologics Reports Full-Year 2023
Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&ndash; The independent data monitoring committee
(IDMC) recommended the continuation of VIRAGE</I>, <I>the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic
Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- VIRAGE remains on track to complete enrollment
in the first half of 2024-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- As of December 31, 2023, Theriva Biologics
reports $23.2 million in cash, which is expected to provide runway into the first quarter of 2025 -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Conference call and webcast to be held on
Monday, March 25 at 8:30 a.m. ET -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, March 25, 2024 </B>&ndash; Theriva&trade;
Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
in areas of high unmet need, today reported financial results for the full-year ended December 31, 2023, and provided a corporate update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;With continued advancement of our clinical
programs, we have the opportunity to achieve several important milestones this year,&rdquo; said Steven A. Shallcross, Chief Executive
Officer of Theriva Biologics. &ldquo;VIRAGE, our Phase 2b trial of VCN-01 in newly-diagnosed metastatic PDAC remains on track to complete
enrollment in the first half of 2024. We completed the first safety review with the IDMC, and with a positive recommendation, VIRAGE will
continue to enroll patients as planned with no modifications to the protocol. Our clinical data has demonstrated that repeated systemic
dosing of VCN-01 is feasible from a safety perspective, and will now focus on determining whether the repeated-dose regimen of VCN-01
may lead to improved clinical outcomes for patients with PDAC and other solid cancers. In addition to advancing the VIRAGE PDAC trial,
we continue to work closely with key opinion leaders, and regulatory agencies to refine our protocol and clinical strategy for VCN-01
as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma. In parallel, our investigator sponsored Phase 1 trial
evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma continues to progress and
will further inform our clinical development pathway in this area of high unmet need.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recent Program Highlights and Anticipated
Milestones:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>VCN-01:</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1%">&nbsp;</TD><TD STYLE="width: 2%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pancreatic
Ductal Adenocarcinoma (PDAC):</B> Dosing is underway and enrollment continues to progress for VIRAGE, the randomized, controlled, multicenter,
open-label Phase 2b trial of VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy
in newly diagnosed bmetastatic PDAC patients. <B>The trial is expected to enroll 92 evaluable patients and remains on track to complete
enrollment in H1 2024.</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The Independent Data Monitoring Committee (IDMC) recommended the continuation
of enrollment as planned into the VIRAGE study. According to the IDMC's expert assessment of clinical data from patients enrolled at six
sites open in the U.S. and nine sites in Spain, the ongoing Phase 2b trial will continue without any changes to the protocol. No safety
concerns were raised based on the evaluation of data presented at the IDMC meeting. Intravenous VCN-01 has been well tolerated and demonstrated
a safety profile consistent with prior clinical trials. Importantly, no additional toxicities were observed in patients receiving a second
dose of VCN-01.</P></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="image_002.jpg" ALT=""> &nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1%"></TD><TD STYLE="width: 2%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Retinoblastoma:
</B>The investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory
retinoblastoma has completed patient treatment. The trial is designed to evaluate escalating doses of VCN-01 administered by two intravitreal
injections separated by 14 days. <B>The investigator sponsored Phase 1 trial, which will complete patient follow-up in H1 2024, will
help inform the planned Phase 2 trial design.</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>This builds on positive preclinical results presented by collaborators at Fundaci&oacute; Sant Joan de D&eacute;u demonstrating that
administration of VCN-01 in combination with topotecan chemotherapy may improve VCN-01 activity against retinoblastoma.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>SYN-004 (ribaxamase)</I>:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1%"></TD><TD STYLE="width: 2%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dosing
is underway for the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic
hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). SYN-004 appeared to be
well tolerated in HCT patients treated with IV meropenem and SYN-004 was not detected in blood samples from the majority of the evaluable
patients. <B>The trial is on track to complete enrollment into the second cohort in Q2 2024.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Business Updates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U></U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif">On November 2, 2023, Theriva signed an exclusive option to license intellectual
property from Sant Joan de D&eacute;u-Barcelona Children&rsquo;s Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination
with topoisomerase I inhibitors. This strengthens a long-term research collaboration with SJD and builds on ongoing trial evaluating VCN-01
in pediatric cancers. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Theriva is actively pursuing licensing discussions for our SYN-020 intestinal
alkaline phosphatase asset.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Full-Year Ended December 31, 2023 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses decreased to $7.1 million for the
year ended December 31, 2023, from $9.9 million for the year ended December 31, 2022. This decrease of 28% is primarily comprised of the
decrease in the fair value of the contingent consideration of $2.8 million, along with lower salary, investor relations, legal costs,
consulting fees related to the VCN acquisition, and director and officer insurance offset by higher audit fees, and other consulting fees.
The charge relating to stock based compensation expense was $0.4 million for the year ended December 31, 2023, compared to $0.4 million
for the year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses increased to $14.3 million for the
year ended December 31, 2023, from $11.7 million for the year ended December 31, 2022. This increase of 22% is primarily the result of
higher clinical trial expenses related to our VIRAGE Phase 2 clinical trial of VCN-01 in PDAC, offset by lower expenses related to our
Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients, the completed Phase 1a clinical trial of SYN-020, decreased
manufacturing expenses related to our Phase 1a clinical trial of SYN-020 and lower other indirect costs. We anticipate research and development
expense to increase as we continue enrollment in our VIRAGE Phase 2 clinical trial of VCN-01 in PDAC and our ongoing Phase 1 clinical
trial in retinoblastoma, expand GMP manufacturing activities for VCN-01, and continue supporting our VCN-11 and other preclinical and
discovery initiatives. Research and development expenses also include a charge relating to non-cash stock-based compensation expense of
$165,000 for the year ended December 31, 2023, compared to $112,000 for the year ended December 31, 2022. In addition, we expect research
and development expenses to increase as we incur higher clinical program costs for our VCN product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other income was $1,442,000 for the year ended December 31, 2023, compared
to other income of $471,000 for the year ended December 31, 2022. Other income for the year ended December 31, 2023 is primarily comprised
of interest income of $1,439,000 and an exchange gain of $3,000. Other income for the year ended December 31, 2022 is primarily comprised
of interest income of $512,000 offset by an exchange loss of $41,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents totaled $23.2 million
as of December 31, 2023, compared to $41.8 million as of December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audited financial statements for the year
ended December 31, 2023 included in the Company&rsquo;s Annual Report on Form 10-K contain an unqualified audit opinion from the Company&rsquo;s
independent registered public accounting firm that includes an explanatory paragraph related to the Company's ability to continue as a
going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics will host a conference call on Monday, March 25,
2024 at 8:30 a.m. ET to discuss its financial results for the full-year ended December 31, 2023 and provide a corporate update. Individuals
may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference
ID: 13744453. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access
the live and archived webcast of this call via the &ldquo;News &amp; Media&rdquo; section of the company&rsquo;s website, <FONT STYLE="color: #0563C1">https://www.therivabio.com</FONT>,
under &ldquo;Events&rdquo; or by clicking here, up to 90 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Theriva&trade; Biologics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Theriva&trade; Biologics (NYSE American: TOVX),
is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.
The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger
tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response
by the patient&rsquo;s immune system. The Company&rsquo;s lead candidates are: (1)&nbsp;VCN-01, an oncolytic adenovirus designed to replicate
selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive
barrier to cancer treatment; (2)&nbsp;SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics
within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin
resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic
cell transplant (HCT) recipients; and (3)&nbsp;SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP)
produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics&rsquo;
website at&nbsp;www.therivabio.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions,
and include statements regarding VIRAGE remaining on track to complete enrollment in the first half of 2024, cash being expected to provide
runway into the first quarter of 2025, </I>continued advancement of the Company&rsquo;s clinical programs providing the opportunity to
achieve <I>several important milestones this year, VIRAGE remaining on track to complete enrollment in the first half of 2024, VIRAGE
continuing to enroll patients as planned with no modifications to the protocol, determining whether the repeated-dose regimen of VCN-01
may lead to improved clinical outcomes for patients with PDAC and other solid cancers, continuing to work closely with key opinion leaders,
and regulatory agencies to refine our protocol and clinical strategy for VCN-01 as an adjunct to chemotherapy in pediatric patients with
advanced retinoblastoma, the Company investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in
pediatric patients with refractory retinoblastoma further informing the Company&rsquo;s clinical development pathway in this area of high
unmet need, the VIRAGE trial enrolling 92 evaluable patients, completing patient follow-up in Q1 2024 in the investigator sponsored Phase
1 trial evaluating VCN-01 in pediatric patients with refractory retinoblastoma, the SYN-004 trial being on track to complete enrollment
in the second cohort in Q2 2024 and expected increases in research and development expenses as the Company incurs higher clinical program
costs for its VCN product candidates. Important factors that could cause actual results to differ materially from current expectations
include, among others, the Company&rsquo;s and VCN&rsquo;s ability to reach clinical milestones when anticipated, including the ability
to continue to enroll patients as planned and the completion of enrollment in Virage in the first half of 2024, completion of patient
follow- up in Q1 2024 in the investigator sponsored Phase 1 trial patient evaluating VCN-01 in pediatric patients with refractory retinoblastoma,
and completing enrollment in the SYN-004 second cohort in Q2 of 2024, generating clinical data that establishes VCN-01 may lead to improved
clinical outcomes for patients with PDAC and other solid cancers; the Company&rsquo;s and VCN&rsquo;s product candidates demonstrating
safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and
achieve the desired results and benefits,; the ability to obtain regulatory approval for commercialization of product candidates or to
comply with ongoing regulatory requirements, regulatory limitations relating to the Company&rsquo;s and VCN&rsquo;s ability to promote
or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful
development, marketing or sale of the Company&rsquo;s and VCN&rsquo;s products, developments by competitors that render such products
obsolete or non-competitive, the Company&rsquo;s and VCN&rsquo;s ability to maintain license agreements, the continued maintenance and
growth of the Company&rsquo;s and VCN&rsquo;s patent estate, the ability to continue to remain well financed and the cash providing a
runway into the first quarter of 2025, and other factors described in the Company&rsquo;s Annual Report on Form&nbsp;10-K for the year
ended December&nbsp;31, 2023 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports
on Form&nbsp;8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no
obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise,
except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Calabrese&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ccalabrese@lifesciadvisors.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">917-680-5608</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva Biologics,&nbsp;Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands except share and par value amounts)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 66%; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 15%; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 15%; padding-bottom: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-align: center; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current Assets</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;23,177</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;41,786</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax credit receivable</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,812</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2,414</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;3,734</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 19.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Current Assets</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;27,403</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;45,520</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Current Assets</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">422</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">345</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;102</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;99</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of use asset</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,759</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,199</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In-process research and development</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;19,755</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;19,150</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,700</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,525</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposits and other assets</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;78</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;23</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Assets</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;55,219</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;71,861</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-align: center; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liabilities and Stockholders&rsquo; Equity </B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current Liabilities:</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;770</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;915</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2,995</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,496</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued employee benefits</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,517</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,403</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent consideration, current portion</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2,973</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred research and development tax credit-current portion</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;906</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loans payable-current</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;63</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;57</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liability-current portion </FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;487</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;216</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Current Liabilities</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;6,738</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;7,060</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-current Liabilities</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current contingent consideration</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;6,274</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;7,211</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Payable - non-current </FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;162</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;221</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities, net</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,618</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current deferred research and development tax credit</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;906</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current operating lease liability</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,442</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,187</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Liabilities</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;15,522</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;17,297</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments and Contingencies</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Temporary Equity</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series C convertible preferred stock, $0.001 par value; 10,000,000 authorized;275,000 issued and outstanding</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2,006</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;2,006</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series D convertible preferred stock, $0.001 par value; 10,000,000 authorized;100,000 issued and outstanding</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;728</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;728</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo; Equity:</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt"><P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Common stock, $0.001 par value; 350,000,000 shares authorized, 17,868,282
issued and 17,148,049 outstanding at December 31, 2023 and 15,844,061 issued and 15,123,828 outstanding at December 31, 2022</P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;18</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;16</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;346,519</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;343,750</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury stock at cost, 720,233 shares at December 31, 2023 and at December 31, 2022</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(288)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(288)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated other comprehensive income (loss)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;32</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(679)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 13.2pt; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(309,318)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(290,969)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Stockholders&lsquo; Equity</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;36,963</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;51,830</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 0.05pt; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Liabilities and Stockholders&rsquo; Equity </B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;55,219</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 0.05pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-bottom: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; padding-right: 3pt; padding-bottom: 0.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;71,861</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva Biologics,&nbsp;Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations and Comprehensive
Loss</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share and per share amounts)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 72%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the&nbsp;year ended</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating Costs and Expenses:</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;7,120</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;9,858</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;14,311</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;11,723</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Operating Costs and Expenses</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;21,431</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;21,581</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loss from Operations</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(21,431)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(21,581)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other Income:</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exhange gain (loss)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;3</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(41)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,439</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;512</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Other Income</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,442</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;471</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 12pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Loss before income taxes</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(19,989)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(21,110)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax benefit</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,640</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;1,425</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Loss Attributable to Theriva Biologics,&nbsp;Inc. and Subsidiaries</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(18,349)</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(19,685)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Warrant exercise price adjustment</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(340)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Loss Attributable to Common Stockholders</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(18,349)</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(20,025)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Loss Per Share&nbsp;- Basic and Dilutive</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(1.14)</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(1.31)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted average number of shares outstanding during the period&nbsp;- basic and dilutive</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;16,107,014</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;15,327,328</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Loss</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(18,349)</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(19,685)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain (loss) on foreign currency translation</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding-right: 3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;711</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(679)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total comprehensive loss</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(17,638)</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;(20,364)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>syn-20240325.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaD2bOdzZR+qYkxtmB0bYkq/ykivbe+vSo8Wt+24RAI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:syn="http://syntheticbiologics.com/20240325" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20240325">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20240325_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20240325_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>syn-20240325_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>syn-20240325_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20240325.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBH;N\M
MK"V>YNYXX(4&6DD8*!^-"5P)J*\F\4?&&.+?:^'HO,;H;J5?E'^ZO?ZG\JP=
M#^)WB'0;D1ZW'->6\OSXF79( >ZG'3VZ?2NZ. K./-;Y=3!UX)V/=Z*YVQ\4
M6WB/1Y9_#MQ;RW@7(AN"5*'_ &AU_'I[UPL?C3Q+X>UB6/68VE5FRT4@Q@>J
M$=OTK*&&G.ZV:Z=2I58QMV/7**Q]#\3:9X@AW6<X$H&6A?AU_#O]15F_UO2M
M+E6*_P!0MK9W&Y5ED"DCUYK%PDI<K6I:DFKW+]%8O_"7^'/^@YI__@0O^-'_
M  E_AS_H.:?_ .!"_P"-'LY]G]S#FCW-JBLXZ_I TXZA_:5K]C#[#/YHV;O3
M/K5BQU"SU.V^T6-S%<0Y*^9$P89'49%)QDE=H=T6:***D84444 %%%% !15>
M]OK73;5[J]N([>!/O22-@"EM+RVO[5+JTGCG@D&5DC;(/XT[.UPOT)Z***0!
M1110 4444 %%%% !7BGQJFF_MS3X?,?R?L^[9GY<[CSCUKVNN#^(7@*?Q6T-
M[972I=6\9012#Y7&2>O8\UV8*I&G64I[&-:+E"R,2R\.:%X*TFPU*:V%_J%T
M@=))Q\D1P#POX_\ ZJW;2 ^,K1H=;TZ*YLSDK<\(T?\ NG_/O5?QK:21Z#HT
M$BXDBBV,,YP0J@UK:9;&X\ P6BSK#)*I1"S8!.XG'XUTU:C6']K:\FW^NQYE
MY/%.">D5>VFOJ>;:W\.]7\/3G5?#-X]Y;Q'(:!OWT7UQU_#\JZ+P?KU[XWMV
MTOQ!HC7448(^WJNS8??T/T_*MS2/+\%V]S/K5XD?FXV0*VYFQW KEM<^(=_J
M!:UTB(V<#'&4_P!8^?<=/P_.HP]6OBJ2YX6??:QTQDHKFEI?H1^%;)+#XG?9
M8F8Q02S(FX\X 8<UV_BSP#8^+;Z"ZNKNYA:&/RP(MN",D]Q[USO@3PEJUOJ\
M6L7R^2BAB%D^^^01G';KWKT^IQ59QJJ4):I6N;T87@U)=3P#X@^!;+PA:6,M
MI=7$QN'96$N., =,#WK=\,_"G2];\.6.I37]Y')<1[F5-N!R1QD>U7?C=_R#
MM(_ZZR?R6NP^'_\ R(>D?]<?_9C71/$55A8S4M6V1&G'VK5M#D?&OARW\+?"
MV73K::6:/[6DFZ3&<D^WTJ#P%XRT7PSX&B74;K$SW$A6&-=SD<<X[?C70?%S
M_D1)O^N\?\ZY3X7^!M,UC2Y-7U6+[2#*8XH22%&,9)QUZTH2C/"N59OXOO&T
MU5M#L=AI?Q3\,ZG=);^?-:NYPIN$VJ3]02!^-=J#D9'2O&_BEX*TK1]+@U;2
MX!;'S1%+&I.UL@D$ ]#Q4\_BF]MO@I9S+*PNIF-F)<G<%!89SZ[5Q6,L-"<8
MSH]7;4M591;4^AU^L_$KPWHUR]M)=/<3IPRVZ[]I]">E2:'\0_#NO7*VMO=-
M#<OPL5PNPL?0'H3[9KS3P*O@:TTS[5X@N(9K^1C^YEC9EC4'C@#!)ZU%X[7P
M9-:Q7WAJZCAO4<!X(D95=?49& 0:V^J4N;V=I7[]"/:SMS77H>TZYK=GX>TM
M]1OBX@1@IV+N.2<#BL)_B5X:CTF+4'NI%25F5(MF9&QU.WL/<UR6MZS+KOP1
MCO+ABTXD2*1C_$5?&?Q&*R_AEX$L/$%I-JFJJ\L"2>5%"&*AB!DDD<]ZRAAJ
M4:;G5OH[:%.I)R2AU1V7BG5O#WB+X?QW]^]Y#I\\P$;QH/,5P6 .,XQP:-!U
M_P .>%_ EK=VIO9--\YH_-:/+E\G)([#BJ7Q/TVTTCX=165C"(;>.Z3:@).,
M[B>ON:3P-I$>N_"2339<?OVE"D_PMNRI_ XIJ,/8*3;Y>;;R"\N>W6QW6AZY
M9>(=,34-/=F@9BOS#!!!Y!%2:MJEKHNF3ZA>N4MX1EB!D]<  >M>3?"/5Y-,
MUR^\.7>4,A+(I_AD3AA^(_\ 0:N?&+6GFEL?#EJ2TDC"655ZDGA%_F?RK-X3
M_:/9+;?Y#]K^[YNIVUAXZT*^TB;5?M#6]E%)Y9DN%V;FQG"CO^%8LWQ?\,12
M;4-Y*,_>6' _4@U=;P;I$/@"WT7576&W@5999]P7;)G+-D].I'TK!6;X4VD/
MV;;9R #!<QN['_@6/Y4X4Z$F[1D]>G8)2FK:I'::!XMT;Q*K?V;=AY$&6B<;
M7 ]<'M]*VZ^=;"XL-'^)MK)X?N6EL#<HL9Y'RO@,ISR>I%?1598J@J4ER[-=
M2J51S3OT"BBBN0V"BBB@#C_'N/(LQ[M_2LV]@?6_ 4=AII62\@D$C1 X; +=
M,]>M=KJ6EVNJP>5<IG'W6!P5^E<3J/AC4-(E^TV3M+&IR&CX9?J/\*]7#U(3
MIQIWM).Z['AXF%:C7E74>:+5G;=')Z?X1UC6&:[U*1K2V7A[B\)SQV /)KJ=
M&&B:-J%O;:5;?:)VD57O+@9/) .T=JABM]:\23#<TDBKQO?A5KK='\*6FFE9
MI3Y]PO(8\*I]A6U>I&*:J/7LOU_KY$4IUJ\DZ,;1[O\ 3_@?>;]%%%>(>^>5
M?&[_ )!VD?\ 763^2UV'P_\ ^1#TC_KC_P"S&K?B'PMI?BB*"/4XY'6!BR;'
M*\GKT^E7]+TVWTC38-/M%9;>!=J!FR<9SUKKG6B\/&FMTS)0:J.1R'Q<_P"1
M$F_Z[Q_SIOPA_P"1%3_KYD_I75:YH=EXATUK#4%=H&8.0C;3D=.:-"T*Q\.Z
M:+#3U=8 Y?#MN.3UYH]M'ZO[+K>X<C]IS>1R7QA_Y$E?^OM/Y-7-6>A3Z[\$
M8([5"]Q;SO.B#JV&8$#WP3^5>HZ]H%AXCT\6.HH[0!Q)A'VG(SW_ !I^BZ-9
M>']+CT^Q5DMXR2H=MQR3D\U<,2H48Q6Z=R94^:;;VL>+^!]6\&I8_8/$FF6Z
M7*,=MT\18.#V;'((KH-3USX8V#1+!I5O>EW ;R83A%[DDXS]!78:S\/_  WK
MMPUQ<V(2=CEI(&V%C[XX/Y5#I?PU\+Z7<K<1V1GD4Y4W#[P#].E;2Q%&3YVY
M)]KZ$*G-::&3\0;/3[+X82II<,<-H\D4B+&, [F!S4WP@_Y$C_MY?^0KK=:T
M:Q\0:8^G7RLUNS*65&VG(.1R*;H6@V/AS3_L.GJZP;R^'?<<GW_"N9UDZ#IO
M>]S3D?M.;I8Y/XP_\B0/^OJ/^35/\)?^1"M_^NTO_H5=+KV@V'B/3OL.HJ[0
M!Q)A'VG(SW_&G:'HMCH&F)8:>K+;JQ8!GW').3S1[:/U?V76]Q\C]IS>1Y'\
M1[&;POXZL_$5FNU)W$W'3S%QN'XC'YFD\#03>-/B-=>(+N/]S;MY^T\@-TC7
M\ ,_\!KUG7_#^F^)+%+/4XR\:N'7:VU@?8_C3= \-Z9X9LY+;38FCCD?>Y=B
MQ)QCJ:W^N1]ARV]ZUK^1G[%\]^FYPOQJDNUTC34C+BT:9O-QT+ #;G_QZHO"
MT/PY'ABTDO#IYNA&#<?:F_>;^_![9Z8KTV_L+34[*2TOH(Y[=Q\R..*Y ?"?
MPH9O-$%P5SG9YYV_3U_6IIXBG[%4Y-JW;J.5.7/S*S]3RBXNM+O/B1:RZ+;+
M!8?:X5B55V@X*@G';)R:^CZY67X?>&Y-3M[U;0Q36VSRTBD*J-IR.*ZJHQ5>
M%7EY;Z+J52@XWN%%%%<1L%%%% !1110 BJ%&%  ]!2T44 %%%% !1110 444
M4 %9'B3G2U&%.9XQAFP#\PX)]*UZCF@BN(S'-&DB'JK#(JZ<N62D9U8<\'%=
M3#T8"'5[F$)%$&B5Q'!)O0<D9/H:BAEGC\*W<D+,)!-)\R\D+YAR1]!FM^"U
MM[52+>".('J$4#-/CBCB0K&BJI).%&!D]:V=9-WMV_ YXX:2C:_?\?\ (YV>
M+3[3[#+I3J;EY4"['W&5#][=ZC'.35]IDB\3MYDBHILQC<V!]^K\-C:6\K20
MVT4;MU9$ )I)[&TNF#7%M%*P& 70' I.K%[WV?KJ"H22NK+5.VMM/\S.UAXY
M;G3XYY,6$K-YC!L*QQ\H)]":;9);VVNM!I[#[.8=TT:'*(V>#[$C/%:QMH#;
M_9S#&8<8\O:-N/I1!;06L>RWA2).N$4 4O:I0Y?Z]?4IT&ZG.[='Y^GH<U(M
MO.+^6\CBFO$F9=DTWE^7'_"5]..]3M<FY\%B;+YP!EVRW#XY-;DUE:W$BR36
MT4CKT9T!(I_V>'R3%Y2>6>2FWCKGI5NO'339HR6%DN;5:IK[^K_K[C*U;RY-
M2LH+MMMDX8L"V%9QC /ZU)IR64%]<Q6,K% JEXEYC1O8]C[5I30Q7$9CFC61
M#U5AD&D@MX;:/RX(DB3^ZBX%9^T7)R_\,;>Q?M.?3]=MO3^K=3E+<0PS03NL
M=P'N<+=12D39+=&4]NQ'I77U7%C:+<FX%M$)C_RT"#=^=6**M13::##T7233
M_K^OZ;"BBBL3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140419100688384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 25,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERIVA BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TOVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M='@//GL?)=-[*CG_5U/\!%!+ P04    "  //7E8EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  \]>5BJQ"(6,P$
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M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    "  //7E8)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ #SUY6&60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M"  //7E8!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    (  \]>5C=E=BI[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  \]>5B97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ #SUY6/@'G39H!   *1$  !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  \]>5B?H!OP
ML0(  .(,   -              "  :P,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ #SUY6)>*NQS     $P(   L              ( !B \  %]R96QS
M+RYR96QS4$L! A0#%     @ #SUY6*K$(A8S 0  (@(   \
M ( !<1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  \]>5@D'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    (  \]>5AED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm249466d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>syn-20240325.xsd</File>
    <File>syn-20240325_lab.xml</File>
    <File>syn-20240325_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm249466d1_8k.htm">tm249466d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm249466d1_8k.htm": {
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20240325",
   "dts": {
    "schema": {
     "local": [
      "syn-20240325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20240325_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20240325_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm249466d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://syntheticbiologics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm249466d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm249466d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001104659-24-038166-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-038166-xbrl.zip
M4$L#!!0    (  \]>5CG=LNK+@,  /X+   0    <WEN+3(P,C0P,S(U+GAS
M9+56VW+:,!!][TS_0?4K8QMP:!,"R:3)I,,,:3K07%\ZLKV !B$YDLRE7U_)
M%VX& K3UD[PZY^RN=E=VXW(ZHF@,0A+.FE;%*5L(6,!#POI-ZZ%K7W6O6RT+
M75Y\_(#TT_ADV^B6  WKZ(8'=HOU^#GZCD=01]^ @<"*BW/TB&EL+/R64!#H
MFH\B"@KT1NJICFI.M>(CV]Y#]Q%8R,5#IS77'2@5R;KK3B83A_$QGG QE$[
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MI+Q23*.3,:K54@3_G+K<U5GM-.?]3)U.F$L)@LJP[U-^^R;=, V7&6ZF/[=
MYJKW[4W:93,W)SPQ!Z-R'LC3?V4RY"UGNE8E/>:>D Z=L"J9:;,3TFZ*#]>2
MTKC^U/NOTCROUZ_@!_)!,ID-!^>+U\#@=3R3UP&3F\,KE!:#'C&Z6+EF8&;
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M]X6=/W8I:15/F/1BNE:0CS.%?.FGK>DMU[C^^'=9D8]/'.BF,PL))H:@^(B
MA>M3S.12%!1 T)Q?@35W<O7]1XJW$- A]_#6Y6P1W^$K]>('2'9(O/5ZR)DQ
M<*=TZKC$6\+>5<38JSR_31W(L.?I6F/,H"#'W0AJP80%81%KM($Y(P.FFW?(
M*3:B/$@Y\SXUY#H8%.$.6)?+# TDX)H@A,E4=ZG!S*FCSXD#B;LSG(N1_@!S
M (BI7^J)AM!:YQ3@@'2->= V-'5 CN-P$N58_SCDP&&,G#.#V51/M0T8._5J
MQWI6R7KD'E;W(_S]+X,^:JW3'U\H6[-["SJ_GU+ ?FL5IT_K9V #67'2:_EA
MP0^^GVWN@M*Q*)T:?GGFQ$=@UGY7_WYU5=>MTJ,W8 :FJ3-JB,-EX=@<2T8X
M0)<\:91/$L-S<@4=ZR7W5^D^/<!7F"!BA38:\4 %*2A%W]17=O]PT^] /B:-
MMUVBY*4L=#R,7>/9657ZV[[C"H:>J7,55&*,/D 4A%"HQQMWOU69S<?="ZFQ
M75:TB7&OTQ"V[./GM>PE,6 ^'C7K9BT7:$960I8=V<Q>V'5!RGH]?YOV,YIV
ML U[93.,EWA459QFP:G;OAP.DS)H?C%3>I_53D_?;D%D$Q-/IB5LZN7G-74@
M*J.&J'HPFLL%+:,<# XW,WRO[V_3?T;3;\:;?MMQILQ^T &*QIE5;A0_37YL
M=W+L$0ZP1E'8#2HOW0WR+%,X4#=S [_O\[K!GBJG4/[FE3+,AF+(BCM=AJZ?
M\DL;D,FNBI0$PE[% 8Y[MHKSH:UBG0V!XE*V\.B=XC[>"//.HZECHD(A[SRT
M1QX^B;U&I=_H[YTE-6]U:L%CLO@4)FV*D$AO/AF8^H%S^!)87-?C4UCL^$>H
MA!I9$(' ^^[&')XL7717&^A/E(+?[C&^UKHK^T[8(?!CUUQ6!L+^XZ? ^H<"
M_:*SBS/[L?M^JWA"$YL"81HG01.I-]6;(^#9)K=4GS+R'RDK23*Q\+837B9Y
MQ-3W1.WLRBY7Y'_FR]_W1\\=XX7?'E9FO>+HIM-_[(YD!$E8\G*ZUK_\^\NK
MD6IIQ:J#_"/YJ"GMM9N%V^GYZ"-]TCX?QIGU+;XX.L+R5]*USM=>B]0%0FIL
MH(A?-4EJ&[B7CRO*<Z**I688=0,QF8DC0-%UX!3'O3<">2<"'I&1;=ZY8\Q
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M3F#,]RDN?@!H\6H&D0&M<YYXT_;!6[XED<*L7TT.2\+RY;".W6;T)C-@X!A
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M&7+711I$D@06 0H:<'M >$C83Y_9$9*]('X@;KC#2!![MW0$-\.U#(<_8AH
M+!J-S053V2KQV!%>CP4,F :PX;I29-VR+F F0C1T&1DPUP$2V][Z+$"FC SR
M&7AP0&#5-"+MHWJ-T.JP2LZNUPL+?\=AQ'LC*>^_"?O[#9 %@\6=9@N4)-4@
M*+!SXC2G&;:W,M6P^^6OJS-R,H3?;0KC7W_]XW]!/%'B\!L6A+S'@; 2^5@!
M,==GDEFI-R(.NV&N\%$>*WG(X@C'=%@(L"J"C% :PAZA>).[%#"7(K$Z(.=
M_(:2S2G<)3EC !J(Q!Z(5.(QYA@P!&P>4:P 3_52M10HM20EL*1PU&TCU&U*
M!TSA,9Q>,X@#*[1% *,","3V0;^PZK*W;#6$\=IU?L3BS9]25RDEB,MU;G /
M4+ BGD4<I+NZO05(Z0=T"//< N/0&R8Q*GQ$>@PZ=X0[2>T!APTG(?P)8 /X
M$'^F,!Z()A9&P@/(HP$()-P%XW4@P0 %QQUR%<%#'CFIDBN0XZX=B! FZ\"
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MLO_I^O/%N_\'4$L! A0#%     @ #SUY6.=VRZLN P  _@L  !
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H-#DT-C9D,5]E>#DY+3$N:'1M4$L%!@     %  4 1 $  -I,      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>tm249466d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20240325.xsd" xlink:type="simple"/>
    <context id="AsOf2024-03-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-03-25" id="ixv-282">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-03-25" id="ixv-283">0000894158</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-03-25" id="ixv-303">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-03-25" id="ixv-304">2024-03-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-03-25" id="ixv-305">THERIVA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-03-25" id="ixv-306">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-03-25" id="ixv-307">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-03-25" id="ixv-308">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-03-25" id="ixv-309">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-03-25" id="ixv-310">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-03-25" id="ixv-311">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-03-25" id="ixv-312">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-03-25" id="ixv-313">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-03-25" id="ixv-314">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-03-25" id="ixv-315">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-03-25" id="ixv-316">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-03-25" id="ixv-317">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-03-25" id="ixv-318">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-03-25" id="ixv-319">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-03-25" id="ixv-320">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-03-25" id="ixv-321">TOVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-03-25" id="ixv-322">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-03-25" id="ixv-323">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
